Bio Medica Laboratories Ltd
Incorporated in August 2015,
Bio Medica Laboratories Ltd
specialises in manufacturing
pharmaceutical parenteral
formulations, producing a
wide range of ethical drugs,
generic drugs, and over-the
-counter (OTC) medications[1]
- Market Cap ₹ 163 Cr.
- Current Price ₹ 130
- High / Low ₹ 148 / 102
- Stock P/E 16.7
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 64.2 %
- ROE 99.5 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 79.0%
- Debtor days have improved from 62.2 to 39.2 days.
Cons
- Working capital days have increased from 68.4 days to 135 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 16.23 | 15.25 | 38.20 | |
| 14.53 | 9.61 | 22.83 | |
| Operating Profit | 1.70 | 5.64 | 15.37 |
| OPM % | 10.47% | 36.98% | 40.24% |
| 0.02 | 0.09 | 0.13 | |
| Interest | 0.77 | 0.97 | 1.35 |
| Depreciation | 0.50 | 1.11 | 1.01 |
| Profit before tax | 0.45 | 3.65 | 13.14 |
| Tax % | 26.67% | 31.51% | 25.49% |
| 0.33 | 2.50 | 9.79 | |
| EPS in Rs | 33.00 | 250.00 | 10.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 150% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 292% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 79% |
| Last Year: | 100% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 9.18 |
| Reserves | 2.34 | 4.84 | 5.55 |
| 9.60 | 10.49 | 15.01 | |
| 5.53 | 4.10 | 9.37 | |
| Total Liabilities | 17.57 | 19.53 | 39.11 |
| 8.31 | 8.73 | 7.68 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 9.26 | 10.80 | 31.43 | |
| Total Assets | 17.57 | 19.53 | 39.11 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 2.29 | 1.62 | -3.67 | |
| -1.69 | -1.54 | 0.34 | |
| -2.13 | -0.08 | 3.33 | |
| Net Cash Flow | -1.52 | 0.00 | 0.00 |
| Free Cash Flow | 0.58 | 0.09 | -3.62 |
| CFO/OP | 147% | 31% | -16% |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 91.53 | 56.01 | 39.18 |
| Inventory Days | 308.79 | 807.82 | 677.70 |
| Days Payable | 361.04 | 222.51 | 159.90 |
| Cash Conversion Cycle | 39.28 | 641.32 | 556.97 |
| Working Capital Days | -24.74 | 95.26 | 134.63 |
| ROCE % | 33.64% | 64.16% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Ampoule Capacity Utilization % |
|
||
| Ampoule Installed Capacity Nos. per Annum |
|||
| Ampoule Production Volume Nos. per Annum |
|||
| New Product Revenue Share % of Revenue from Operations |
|||
| Top 5 Customer Revenue Concentration % of Revenue from Operations |
|||
| Vial Capacity Utilization % |
|||
| Vial Installed Capacity Nos. per Annum |
|||
| Vial Production Volume Nos. per Annum |
|||
Extracted by Screener AI
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
6 July 2026 - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.
-
Shareholders meeting
23 June 2026 - Postal ballot seeks approval to add essential oils business objects; e-voting runs 24 June–23 July 2026.
-
Amendment to AOA/MOA
22 June 2026 - Board approved adding essential oils and allied products businesses to MOA, subject to postal ballot approval.
-
Outcome of Board Meeting
22 June 2026 - Board approved object clause expansion into essential oils business; postal ballot to seek shareholder approval on 22 June 2026.
Business Profile:[1]
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, primarily generic injectable drugs.
The company manufactures liquid injections
and dry powder injections for both human
and veterinary use under a B2B/contract manufacturing model. Products are marketed
by client companies while Bio Medica acts
as the manufacturer.